Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 6/20 | 0.58 |
| ▸ | DRD3 | P35462 | 6/20 | 0.58 |
| ▸ | DRD4 | P21917 | 5/20 | 0.58 |
| ▸ | HTR2A | P28223 | 2/20 | 0.53 |
| ▸ | ADRB1 | P08588 | 13/20 | 0.52 |
| ▸ | ADRB2 | P07550 | 9/20 | 0.50 |
| ▸ | DRD1 | P21728 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11912374 | 0.86 | DRD2 (0.42) | DRD2DRD3DRD4HTR2AADRB1 | |
| SCHEMBL12119317 | 0.81 | DRD2 (0.56) | DRD2DRD3DRD4HTR2AADRB1 | |
| SCHEMBL12115577 | 0.80 | DRD2 (0.58) | DRD2DRD3DRD4HTR2AADRB1 | |
| SCHEMBL10215347 | 0.80 | ADRB1 (0.65) | DRD2DRD3DRD4ADRB1ADRB2 | |
| SCHEMBL13437595 | 0.77 | DRD2 (0.56) | DRD2DRD3DRD4HTR2AADRB1 | |
| SCHEMBL1246145 | 0.75 | DRD2 (0.51) | DRD2DRD3DRD4HTR2AADRB1 | |
| SCHEMBL14643032 | 0.75 | DRD2 (0.54) | DRD2DRD3DRD4HTR2AADRB1 | |
| SCHEMBL14643034 | 0.75 | DRD2 (0.54) | DRD2DRD3DRD4HTR2AADRB1 | |
| SCHEMBL1246294 | 0.74 | DRD2 (0.59) | DRD2DRD3DRD4HTR2AADRB1 | |
| SCHEMBL19043579 | 0.74 | ADRB1 (0.62) | DRD2DRD3DRD4ADRB1ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018059537-A1 | DIAZASPIRO[5.5]UNDECANE DERIVATIVE AND USE THEREOF | 四川海思科制药有限公司 | 2018-04-05 | — | — | WO | disclosed |
| WO-2017125060-A1 | NITROGENOUS HETEROCYCLIC AMIDE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL APPLICATION | 四川海思科制药有限公司 | 2017-07-27 | — | — | WO | disclosed |
| WO-2017114377-A1 | BENZYL HETEROCYCLIC COMPOUND DERIVATIVE AND PHARMACEUTICAL APPLICATION THEREOF | 四川海思科制药有限公司 | 2017-07-06 | — | — | WO | disclosed |
| WO-2017107877-A1 | BIPHENYL DERIVATIVE AND PREPARATION METHOD AND MEDICAL USE THEREOF | 四川海思科制药有限公司 | 2017-06-29 | — | — | WO | disclosed |
| WO-2017063563-A1 | OCTAHYDROCYCLOPENTA[C]PYRROLE DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL USE | 四川海思科制药有限公司 | 2017-04-20 | — | — | WO | disclosed |
| WO-2017063564-A1 | OCTAHYDROCYCLOPENTA[C]PYRROLE DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL USE | 四川海思科制药有限公司 | 2017-04-20 | — | — | WO | disclosed |
| US-9598381-B2 | SMYD2 inhibitors | ABBVIE INC. (US) | 2017-03-21 | — | — | US | disclosed |
| WO-2017012489-A1 | BENZO RING DERIVATIVE WITH Β2 RECEPTOR AGONIST AND M3 RECEPTOR ANTAGONIST ACTIVITIES AND USE THEREOF IN MEDICINE | 四川海思科制药有限公司 | 2017-01-26 | — | — | WO | disclosed |
| US-20160031838-A1 | SMYD2 INHIBITORS | ABBVIE INC. | 2016-02-04 | — | — | US | disclosed |
| US-9040559-B2 | BETA2-adrenoceptor agonists | NOVARTIS AG (CH) | 2015-05-26 | — | — | US | disclosed |
| US-7402598-B2 | Arylethanolamine β2-adrenoreceptor agonist compounds | GLAXO GROUP LIMITED (GB) | 2008-07-22 | — | — | US | disclosed |
| US-7402598-B2 | Arylethanolamine β2-adrenoreceptor agonist compounds | GLAXO GROUP LIMITED (GB) | 2008-07-22 | — | — | US | disclosed |
| EP-1556342-B1 | PHENETHANOLAMINE DERIVATIVE FOR THE TREATMENT OF RESPIRATORY DISEASES | GLAXO GROUP LTD (GB) | 2008-03-26 | — | — | EP | disclosed |
| US-7294650-B2 | Benzothiophen and thiochrone containing phenethanolamine derivatives for the treatment of respiratory disorders | GLAXO GROUP LIMITED (GB) | 2007-11-13 | — | — | US | disclosed |
| US-7294650-B2 | Benzothiophen and thiochrone containing phenethanolamine derivatives for the treatment of respiratory disorders | GLAXO GROUP LIMITED (GB) | 2007-11-13 | — | — | US | disclosed |
| EP-1554264-B1 | MEDICINAL ARYLETHANOLAMINE COMPOUNDS | GLAXO GROUP LTD (GB) | 2007-08-08 | — | — | EP | disclosed |
| US-20070172385-A1 | Benzothiophen and thiochrone containing phenethanolamine derivatives for the treatment of respiratory disorders | GLAXO GROUP LIMITED (GB) | 2007-07-26 | — | — | US | disclosed |
| US-20070172385-A1 | Benzothiophen and thiochrone containing phenethanolamine derivatives for the treatment of respiratory disorders | GLAXO GROUP LIMITED (GB) | 2007-07-26 | — | — | US | disclosed |
| US-20070135490-A1 | Phenetanolamine derivatives | GLAXO GROUP LIMITED (GB) | 2007-06-14 | — | — | US | disclosed |
| US-20070135490-A1 | Phenetanolamine derivatives | GLAXO GROUP LIMITED (GB) | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160031838-A1 | SMYD2 INHIBITORS | SMYD2, SMYD3, NSD1 | DRD2 1794/4885DRD3 1951/4885DRD4 2632/4885 |
| US-20070135490-A1 | Phenetanolamine derivatives | ADRB2, ADRB1, ADRB3 | DRD2 254/4885DRD3 467/4885DRD4 867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.